Skip to main content
. 2022 Aug 16;140(15):1674–1685. doi: 10.1182/blood.2022016293

Figure 3.

Figure 3

OS from randomization in patients with NPM1mut, with or without co-occurring FLT3-ITD, at AML diagnosis. (A) NPM1mut without co-occurring FLT3-ITD. (B) NPM1mut with co-occurring FLT3-ITD. “Other” includes study patients without the specific genetic status at diagnosis.